Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

C. Parker, D. Heinrich, S.I. Helle, Joe O'Sullivan, S. Fossa, A. Chodacki, T. Demkow, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, S. Nilsson, P. Hoskin, D. Bottomley, A. Solberg, N.D. James, I. Syndikus, S.A. Wedel, J. Kliment, A. CrossC.G. O'Bryan-Tear, J. Garcia-Vargas, O. Sartor

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)E130-U523
Number of pages394
JournalEuropean Urology Supplements
Volume11
Publication statusPublished - 2012

Cite this

Parker, C., Heinrich, D., Helle, S. I., O'Sullivan, J., Fossa, S., Chodacki, A., Demkow, T., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Nilsson, S., Hoskin, P., Bottomley, D., Solberg, A., James, N. D., Syndikus, I., Wedel, S. A., Kliment, J., ... Sartor, O. (2012). Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA). European Urology Supplements, 11, E130-U523.